STRO-002-GM2: A phase 1, open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-002, an anti-folate receptor alpha (FolRα) antibody-drug conjugate (ADC), in combination with bevacizumab in patients with advanced epithelial ovarian cancer (EOC, including fallopian tube or primary peritoneal cancers).

被引：0
|
作者：
Naumann, R. Wendel
Martin, Lainie P.
Oaknin, Ana
Spira, Alexander I.
Hamilton, Erika P.
Schilder, Russell J.
Lu, Lin
Kuriakose, Jason
Berman, Craig Jerome
Molina, Arturo
机构：
[1] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA
[3] Hosp Univ Vall Hebron, Vall Hebron Inst Oncol, Vall Hebron Barcelona Hosp Campus, Barcelona, Spain
[4] Virginia Hlth Specialists, Fairfax, VA USA
[5] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[6] Thom Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA USA
[7] Sutro Biopharma, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5622
引用
收藏
页数：1
相关论文
共 13 条
  • [1] A Phase I, open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-002, an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), in patients with advanced epithelial ovarian cancer (including fallopian tube or primary peritoneal cancers) and endometrial cancers
    Naumann, Robert Wendel
    Uyar, Denise S.
    Schilder, Russell J.
    Palumbo, Michael A.
    DeAlmeida, Venita
    Matheny, Shannon L.
    Molina, Arturo
    CANCER RESEARCH, 2019, 79 (13)
  • [2] Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRa expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort
    Oaknin, Ana
    Farinas-Madrid, Lorena
    Garcia-Duran, Carmen
    Martin, Lainie P.
    O'Malley, David M.
    Schilder, Russell J.
    Uyar, Denise
    Moroney, William
    Diaz, John Paul
    Spira, Alexander I.
    Garcia-Donas, Jesus
    Palumbo, Michael
    Dokainish, Hatem
    Liu, Lin
    Berman, Craig Jerome
    Naumann, R. Wendel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Luveltamab tazevibulin, an antifolate receptor alpha (FRa) antibody-drug conjugate (ADC), in combination with bevacizumab (bev) in patients with recurrent high-grade epithelial ovarian cancer (EOC): STRO-002-GM2 phase I study
    Martin, L. P.
    Uyar, D.
    Madariaga, A.
    Spira, A. I.
    Oaknin, A.
    Schilder, R.
    Alia, E. M. Guerra
    Hamilton, E. P.
    Naumann, R. W.
    Lorusso, D.
    Lu, L.
    Berman, C. J.
    Borgman, A. E.
    Moroney, J. W.
    ANNALS OF ONCOLOGY, 2024, 35 : S568 - S569
  • [4] Stability and safety evaluation of STRO-002, a site-specific anti-folate receptor alpha antibody-drug conjugate for the potential treatment of ovarian and endometrial cancers
    Solis, Willy
    De Almeida, Venita
    Abrahams, Cristina
    Li, Xiaofan
    Heibeck, Tyler
    Bruhns, Maureen
    Galan, Adam
    Hoffman, Heidi
    Kiss, Robert
    Hallam, Trevor
    Lupher, Mark
    CANCER RESEARCH, 2019, 79 (13)
  • [5] Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRa) antibody drug conjugate (ADC), demonstrates clinical activity in recurrent/progressive epithelial endometrial cancer (EEC): STRO-002-GM1 phase I dose expansion
    Pothuri, B.
    Naumann, R. W.
    Martin, L. P.
    O'Malley, D.
    Uyar, D.
    Moroney, J. W.
    Diaz, J.
    Garcia-Donas, J.
    Sanchez, A. Redondo
    Martin, A. Gonzalez
    Illescas, D. G.
    Liu, L.
    Berman, C.
    Oaknin, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S508 - S508
  • [6] PHASE 1 DOSE-ESCALATION STUDY OF STRO-002, AN ANTI-FOLATE RECEPTOR ALPHA (FRα) ANTIBODY DRUG CONJUGATE (ADC), IN PATIENTS WITH ADVANCED PLATINUM-RESISTANT/REFRACTORY EPITHELIAL OVARIAN CANCER (OC)
    Naumann, R.
    Braiteh, F.
    Diaz, J.
    Hamilton, E.
    Diab, S.
    Schilder, R.
    Moroney, J.
    Martin, L.
    Uyar, D.
    O'Malley, D.
    Penson, R.
    DiLea, C.
    Palumbo, M.
    DeAlmeida, V.
    Berman, C.
    Matheny, S.
    Molina, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A61 - A61
  • [7] Phase 1 dose-escalation study of STRO-002, an antifolate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced, progressive platinum-resistant/refractory epithelial ovarian cancer (EOC).
    Naumann, R. Wendel
    Braiteh, Fadi S.
    Martin, Lainie P.
    Hamilton, Erika P.
    Diaz, John Paul
    Diab, Sami
    Schilder, Russell J.
    Moroney, John William
    Uyar, Denise
    O'Malley, David M.
    Penson, Richard T.
    DiLea, Clifford
    Palumbo, Michael
    De Almeida, Venita I.
    Matheny, Shannon L.
    Lu, Lin
    Berman, Craig Jerome
    Molina, Arturo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Antitumor activity of STRO-002, a novel anti-folate receptor-α (FRα) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary phase I dose escalation safety outcomes in patients with ovarian carcinoma (OC)
    Uyar, Denise
    Schilder, Russell J.
    Naumann, R. Wendel
    Braiteh, Fadi S.
    Hamilton, Erika
    Diab, Sami
    Moroney, John
    Penson, Richard T.
    Smith, Jennifer
    Abrahams, Cristina
    Palumbo, Michael
    DeAlmeida, Venita
    Matheny, Shannon
    Molina, Arturo
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [9] A phase 1 open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies.
    Krishnan, Amrita Y.
    Shah, Nina
    Spira, Alexander I.
    Kaufman, Jonathan L.
    Niesvizky, Ruben
    Shah, Nirav Niranjan
    Burke, John M.
    Popplewell, Leslie
    Martin, Thomas G.
    Cheung, Julee
    Matheny, Shannon L.
    Leonard, John Paul
    Molina, Arturo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] A Phase I open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies
    Shah, Nirav N.
    Krishnan, Amrita Y.
    Shah, Nina D.
    Burke, John M.
    Melear, Jason M.
    Spira, Alexander I.
    Kaufman, Jonathan L.
    Cohen, Jonathon B.
    Niesvizky, Ruben
    Popplewell, Leslie L.
    Chhabra, Saurabh
    Sharman, Jeff P.
    Martin, Thomas G.
    Matheny, Shannon L.
    Leonard, John P.
    Molina, Arturo
    CANCER RESEARCH, 2019, 79 (13)
12